(S1 (S (S (S (NP (NN TGFbeta1)) (, ,) (PP (ADVP (RB back)) (TO to) (NP (DT the) (JJ future)))) (: :) (S (VP (VBG revisiting) (NP (PRP$ its) (NN role)) (PP (IN as) (NP (DT a) (NN transforming) (NN growth) (NN factor)))))) (. .)))
(S1 (S (S (NP (NN TGFbeta1)) (VP (VBD was) (ADVP (RB initially)) (VP (VBN identified) (PP (IN in) (NP (NP (NN culture) (NNS media)) (PP (IN from) (NP (JJ transformed) (NNS cells))))) (PP (IN as) (NP (NP (NN part)) (PP (IN of) (NP (NP (DT a) (NN factor)) (SBAR (WHNP (WDT that)) (S (VP (MD could) (VP (VB produce) (NP (DT a) (VBN transformed) (NN phenotype)) (PP (IN in) (NP (DT a) (JJ nontransformed) (NN cell) (NN line)))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Subsequently)) (NP (DT this) (NN activity)) (VP (VBD was) (VP (VBN separated) (PP (IN into) (NP (NP (NN TGFbeta)) (CC and) (NP (NN TGFalpha)) (NP (DT an) (NN EGF) (NN receptor) (NN ligand))))))) (. .)))
(S1 (S (PP (IN With) (NP (DT the) (NN discovery) (SBAR (IN that) (S (NP (NN TGFbeta1)) (VP (VBD was) (NP (NP (NP (DT a) (JJ potent) (NN growth) (NN inhibitor)) (PP (IN of) (NP (JJ epithelial) (NNS cells)))) (, ,) (CC and) (NP (NP (DT the) (NN identification)) (PP (IN of) (NP (NP (VBG inactivating) (NNS mutations)) (PP (IN within) (NP (NP (DT the) (NN TGFbeta1) (NN signaling) (NN pathway)) (PP (IN in) (NP (NNS cancers)))))))))))))) (NP (PRP it)) (VP (VBD became) (ADJP (JJ clear)) (SBAR (IN that) (S (NP (NN TGFbeta1) (NN signaling)) (VP (VBZ is) (NP (NP (DT a) (NN tumor) (NN suppressor) (NN pathway)) (PP (IN for) (NP (NP (JJ early) (NNS stages)) (PP (IN of) (NP (NN cancer)))))))))) (. .)))
(S1 (S (S (S (ADVP (RB However)) (NP (JJ many) (JJ human) (NNS carcinomas)) (VP (VBP overexpress) (NP (NN TGFbeta1)))) (CC and) (S (NP (DT this)) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (JJ poor) (NN patient) (NN prognosis)) (CC and) (NP (NP (VBN increased) (NN frequency)) (PP (IN of) (NP (NN metastasis)))))))))) (. .)))
(S1 (S (S (NP (JJ Similar) (NNS results)) (VP (VBP have) (VP (VBN been) (VP (VBN obtained) (PP (IN with) (NP (NP (NN tumor) (NN cell) (NNS lines)) (CC and) (NP (JJ experimental) (NN animal) (NNS models)))))))) (. .)))
(S1 (S (S (ADVP (RB Thus)) (NP (NP (NN stage) (JJ specific) (NN duality)) (PP (IN of) (NP (NN function)))) (VP (VBZ is) (NP (NP (DT the) (VBG emerging) (NN paradigm)) (PP (IN for) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NN TGFbeta1))) (PP (IN in) (NP (NN cancer)))))))) (. .)))
(S1 (S (S (NP (DT This) (NN review)) (VP (MD will) (VP (VP (VB focus) (PP (IN on) (NP (NP (DT the) (NN evidence)) (PP (IN for) (NP (NN TGFbeta1))))) (PP (IN as) (NP (DT a) (NP (NP (NN tumor) (VBG promoting)) (CC and) (NP (NN metastasis))) (NN factor)))) (CC and) (VP (VB examine) (NP (NP (DT the) (ADJP (ADJP (JJ biological)) (CC and) (ADJP (JJ molecular))) (NN basis)) (PP (IN for) (NP (DT these) (NNS effects)))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN proposed) (SBAR (IN that) (S (NP (NP (DT the) (NN switch)) (PP (IN from) (NP (NN tumor) (NN suppressor))) (PP (TO to) (NP (NN oncogene)))) (VP (VBZ reflects) (NP (NP (ADJP (ADJP (JJ genetic)) (CC or) (ADJP (JJ epigenetic))) (NNS alterations)) (PP (IN in) (NP (NP (NN signaling) (NNS pathways)) (PP (IN in) (NP (NN tumor) (NNS cells))))) (SBAR (WHNP (WDT that)) (S (VP (VBP alter) (NP (DT the) (NN readout)) (PP (IN from) (NP (DT the) (NN TGFbeta1) (NN pathway))))))))))))) (. .)))
